Hazard Information | Back Directory | [Uses]
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer[1]. | [in vivo]
Ganitumab (AMG 479; 1 mg/dose; i.p; Na?ve and tumor-bearing mice) inhibits IGF1-induced activation of mIGF1R in murine lungs[1].
Ganitumab (300 μg/dose; i.p.; female athymic nude mice) reduces peripheral blood neutrophils[1].
Ganitumab (300 μg/dose; i.p.; male athymic nude mice) causes impaired glucose tolerance in male mice and increases serum levels of mGH, mIGF1 and mIGFBP3[1].
Animal Model: | Na?ve and tumor-bearing mice[1] | Dosage: | 1 mg/dose | Administration: | Intraperitoneal injection | Result: | Inhibited the IGF1-induced activation of mIGF1R and inhibited 80% tumor growth. |
Animal Model: | Male athymic nude mice[1] | Dosage: | 300 μg/dose | Administration: | Intraperitoneal injection, twice per week for a total of five doses | Result: | Had significantly higher serum glucose levels than hIgG1-pretreated mice.
Increased serum levels of mIGF1, mIGFPB3 and mGH.
|
Animal Model: | Female athymic nude mice[1] | Dosage: | 300 μg/dose | Administration: | Intraperitoneal injection, twice per week for a total of five doses | Result: | Reduced the number of peripheral neutrophils up to 50% compared with hIgG1 controls. |
| [References]
[1] Moody G, et, al. IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice. J Endocrinol. 2014 Mar 17;221(1):145-55. DOI:10.1530/JOE-13-0306 |
|
Company Name: |
DC Chemicals
|
Tel: |
021-8447131 13564518121 |
Website: |
www.approvedhomemanagement.com/showsupplierproductslist927327/0.htm |
Company Name: |
Biolab Reagents
|
Tel: |
18108604356 18108604356 |
Website: |
www.biolabreagent.com/ |
Company Name: |
Cell Sciences
|
Tel: |
9785721070 |
Website: |
www.cellsciences.com |
|